Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc. Issue 9 (19th August 2022)

• Record Type: Journal Article
• Authors: Paschal, Holly M. (Parenica); Kabat, Christopher N.; Papaconstadopoulos, Pavlos; Kirby, Neil A.; Myers, Pamela A.; Wagner, Timothy D.; Stathakis, Sotirios
• Is Part Of: Journal of applied clinical medical physics. Volume 23:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-19
• Subjects: dose calculation -- Monte Carlo -- quality assurance; Medical physics -- Periodicals; Clinical medicine -- Periodicals; Health Physics; Clinical Medicine; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; 610.153
• DOI: 10.1002/acm2.13715
• Languages: English
• ISSNs: 1526-9914

Abstract

Abstract: Introduction: Numerous studies have proven the Monte Carlo method to be an accurate means of dose calculation. Although there are several commercial Monte Carlo treatment planning systems (TPSs), some clinics may not have access to these resources. We present a method for routine, independent patient dose calculations from treatment plans generated in a commercial TPS with our own Monte Carlo model using free, open‐source software. Materials and methods: A model of the Elekta Versa HD linear accelerator was developed using the EGSnrc codes. A MATLAB script was created to take clinical patient plans and convert the DICOM RTP files into a format usable by EGSnrc. Ten patients' treatment plans were exported from the Monaco TPS to be recalculated using EGSnrc. Treatment simulations were done in BEAMnrc, and doses were calculated using Source 21 in DOSXYZnrc. Results were compared to patient plans calculated in the Monaco TPS and evaluated in Verisoft with a gamma criterion of 3%/2 mm. Results: Our Monte Carlo model was validated within 1%/1‐mm accuracy of measured percent depth doses and profiles. Gamma passing rates ranged from 82.1% to 99.8%, with 7 out of 10 plans having a gamma pass rate over 95%. Lung and prostate patients showed the best agreement with doses calculated in Monaco. All statistical uncertainties in DOSXYZnrc were less than 3.0%. Conclusion: A Monte Carlo model for routine patient dose calculation was successfully developed and tested. This model allows users to directly recalculate DICOM RP files containing patients' plans that have been exported from a commercial TPS.